Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Thoracic 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 152Fluorouracil 138Gemcitabine 118Bevacizumab 117Leucovorin 107Specimen Handling 105Capecitabine 96pembrolizumab 91Magnetic Resonance Spectroscopy 83Nivolumab 79Cisplatin 79Irinotecan 72durvalumab 64Cetuximab 62Biopsy 61Paclitaxel 60130-nm albumin-bound paclitaxel 60atezolizumab 46Radiotherapy 46Albumin-Bound Paclitaxel 37Taxes 36Carboplatin 36Folfox protocol 35Drug Therapy 32Cyclophosphamide 30lenvatinib 29dehydroftorafur 29tislelizumab 27sintilimab 27Radiation 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
pevonedistat × Gastrointestinal × 90 days × Clear all
NCT04175912 2026-05-29

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled 11 charts
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡